Lotte Biologics has completed its biopharmaceutical production facility in Songdo International City, Incheon.
On June 14, the city of Incheon announced that Lotte Biologics has finished construction on its first factory at the Songdo Bio Campus and has applied for operational approval from the Incheon Free Economic Zone Authority.
The company began construction in July 2024 on a site in Block Ki20 of Songdo's 11th district, creating a facility with a production capacity of 120,000 liters. To meet customer demand, Lotte Biologics has incorporated a 15,000-liter bioreactor.
With this new facility, Lotte Biologics has increased its total production capacity to 160,000 liters, including the 40,000-liter facility it acquired in Syracuse, New York. If plans proceed as scheduled, the company aims to establish two additional factories of the same size in Songdo, which would bring total production capacity to 400,000 liters.
The company is providing stable services from cell line development to global contract development and manufacturing (CDMO) based on its Syracuse Bio Campus.
A representative from Lotte Biologics stated, "We will enhance our CDMO competitiveness by operating dual sites connecting Syracuse and Songdo."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.